查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2022-2029年全球辅助诊断市场规模研究与预测，按技术、按适应症、按终端用户和区域分析
市场调查报告书
商品编码
1269698

2022-2029年全球辅助诊断市场规模研究与预测，按技术、按适应症、按终端用户和区域分析

Global Companion Diagnostics Market Size study & Forecast, by Technology by Indication, By End User and Regional Analysis, 2022-2029
出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3个工作天内

价格

2021年，全球辅助诊断市场的价值约为68亿美元，预计在2022-2029年的预测期内将以超过11.0%的健康增长率增长。伴随诊断是一种用于确保使用类似生物产品或药物的安全和有效的测试。这些测试通常用于诊断癌症。在此，根据确定的生物标志物推荐适当的药物。基于特定病人的反应，这些测试提供个性化的治疗。由于癌症发病率的上升和不同适应症的新测试的监管批准的增加等因素，辅助诊断市场正在扩大。

根据世界卫生组织（WHO）2022年2月公布的统计数据，全球每年约有40万名儿童罹患癌症，全球癌症发病率的上升正在促进市场增长。另外，根据世界癌症研究基金国际组织公布的统计数据，2020年，全球有18,094,716万例癌症确诊。国际癌症研究机构估计，到2040年，全世界的癌症负担将增加到2750万新病例。由于全球癌症发病率的增加，这些测试的使用量也在增加，这促进了市场的扩张。此外，预计监管部门对这些测试的各种适应症的批准将扩大市场。例如，2022年8月，美国FDA批准赛默飞世尔科技公司的Oncomine Dx目标测试作为辅助诊断（CDx）。该测试可以识别出表现出HER2（ERBB2）激活性突变（SNVs & Exon 20插入）的非小细胞肺癌肿瘤。此外，药物和诊断技术的共同开发以及政府的有利支持正在创造有利可图的市场增长。然而，药物开发和相关临床试验的高成本可能会阻止市场增长。

全球辅助诊断市场研究考虑的主要地区包括亚太地区、北美、欧洲、拉丁美洲和世界其他地区。北美洲在收入方面占主导地位，因为该地区的药物发现活动不断增加，疾病的流行率不断上升，监管部门的批准也不断增加。而亚太地区在预测期内预计将以最高的复合年增长率增长，原因是疾病流行率上升、药物开发合作的数量增加、主要参与者的地理扩张以及政府和非营利组织在市场空间的积极参与。

该研究的目的是确定近年来不同领域和国家的市场规模，并对未来几年的价值进行预测。该报告旨在将研究涉及的国家内的行业的质量和数量方面都纳入其中。

该报告还提供了关于关键方面的详细信息，如驱动因素和挑战，这将确定市场的未来增长。此外，它还纳入了微观市场的潜在机会，供利益相关者投资，以及对竞争格局和主要参与者的技术产品的详细分析。.

目录

第一章：执行摘要

  • 市场简介
  • 2019-2029年全球和细分市场的估计和预测
    • 2019-2029年辅助诊断市场，按地区划分
    • 2019-2029年辅助诊断市场，按技术划分
    • 2019-2029年伴侣诊断市场，按适应症划分
    • 2019-2029年伴侣诊断市场，按终端用户划分
  • 主要趋势
  • 估算方法
  • 研究假设

第二章：全球伴随诊断市场的定义和范围

  • 本研究的目的
  • 市场定义和范围
    • 研究的范围
    • 行业演变
  • 研究中考虑的年份
  • 货币兑换率

第三章：全球辅助诊断市场动态

  • 伴随诊断市场的影响分析（2019-2029）。
    • 市场驱动力
      • 癌症发病率的增加
      • 监管部门对不同适应症的新测试的批准不断增加
    • 市场挑战
      • 药物开发和相关临床试验的高成本
    • 市场机会
      • 药物和诊断技术的共同开发
      • 有利的政府支持

第四章：全球辅助诊断市场行业分析

  • 波特的5力模型
    • 供应商的议价能力
    • 买方的讨价还价能力
    • 新进入者的威胁
    • 替代品的威胁
    • 竞争性的竞争
  • 波特五力模型的未来方法（2019-2029年）
  • PEST分析
    • 政治因素
    • 经济
    • 社会
    • 技术
  • 最佳投资机会
  • 最佳策略
  • 行业专家展望
  • 分析师建议和结论

第五章：风险评估：COVID-19的影响

  • 评估COVID-19对行业的整体影响
  • COVID-19前和COVID-19后的市场情况

第六章：全球辅助诊断市场，按技术分类

  • 市场简介
  • 按技术分類的全球辅助诊断市场，表现 - 潜力分析
  • 2019-2029年全球伴侣诊断市场按技术的估计和预测
  • 伴随诊断市场，次级細項分析
    • 免疫组化 (IHC)
    • 聚合酶链式反应 (PCR)
    • 原位杂交 (ISH)
    • 实时PCR (RT-PCR)
    • 基因测序
    • 其他技术

第7章 ：全球辅助诊断市场，按适应症分类

  • 市场简介
  • 全球辅助诊断市场，按适应症，性能 - 潜力分析
  • 2019-2029年全球辅助诊断市场按适应症的估计和预测
  • 伴随诊断市场，細項分析
    • 肺癌
    • 乳腺癌
    • 结直肠癌
    • 白血病
    • 黑色素瘤
    • 其他适应症

第8章：全球辅助诊断市场，按终端用户分类

  • 市场简介
  • 按终端用户分類的全球辅助诊断市场，表现 - 潜力分析
  • 2019-2029年全球辅助诊断市场按终端用户的估计和预测
  • 伴随诊断市场，次级细分市场分析
    • 制药和生物制药公司
    • 参考实验室
    • CROs
    • 其他

第九章：全球辅助诊断市场，区域分析

  • 伴随诊断市场，区域市场简介
  • 北美洲
    • 美国
      • 技术分类估计和预测，2019-2029年
      • 2019-2029年适应症分类估计和预测
      • 2019-2029年终端用户细分估计和预测
    • 加拿大
  • 欧洲辅助诊断市场简介
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 意大利
    • 欧洲其他地区
  • 亚太地区辅助诊断市场概况
    • 中国
    • 中国
    • 日本
    • 澳大利亚
    • 韩国
    • 亚太其他地区
  • 拉美配套诊断市场简介
    • 巴西
    • 墨西哥
    • 拉美其他地区
  • 世界其他地区

第十章：竞争情报

  • 顶级市场战略
  • 公司简介
    • Abbott Laboratories
      • 关键信息
      • 概况
      • 财务（取决于数据的可用性）
      • 产品摘要
      • 近期发展情况
    • Agilent Technologies Inc.
    • F.Hoffmann-La Roche Ltd
    • Biomerieux SA
    • Qiagen NV
    • Siemens Healthcare Gmbh
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation (Beckman Coulter Inc.)
    • Almac Group
    • Illumina Inc.

第十一章 ：研究过程

  • 研究过程
    • 资料探勘
    • 分析
    • 市场评估
    • 验证
    • 出版
  • 研究属性
  • 研究假设

Global Companion Diagnostics Market is valued at approximately USD 6.80 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 11.0% over the forecast period 2022-2029. A companion diagnostic is a test used to ensure the usage of a comparable biological product or medication is both safe and effective. These tests are typically used to diagnose cancer. In this, an appropriate medicine is recommended based on the identified biomarker. Based on a particular patient's response, these tests offer personalized treatment. The Companion Diagnostics market is expanding because of factors such as the increasing incidence of Cancer and rising Regulatory Approvals of New Tests for Different Indications.

The rising prevalence of cancer globally is fostering market growth, according to statistics published by the World Health Organization (WHO) in February 2022, approximately 400,000 children develop cancer worldwide every year. Also, according to the statistics published by the World Cancer Research Fund International, in 2020, there were 18,094,716 million cases of cancer diagnosed globally. The International Agency for Research on Cancer estimated increase in the worldwide burden of cancer is to 27.5 million new cases by 2040. The usage of these tests is increasing due to the increased incidence of cancer worldwide, which is boosting the market's expansion. Also, it is anticipated that regulatory approvals of these tests for various indications will expand the market. For instance, in August 2022, the U.S. FDA approved Thermo Fisher Scientific Inc.'s Oncomine Dx Target Test as a companion diagnostic (CDx). This test identifies non-small cell lung cancer tumours that exhibit HER2 (ERBB2) activating mutations (SNVs & Exon 20 Insertion). In addition, the co-development of drug and diagnostic technology and favorable government support is creating lucrative growth in the market. However, the high cost of drug development and associated clinical trials may halt market growth.

The key regions considered for the Global Companion Diagnostics Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the rising drug discovery activities, rising prevalence of diseases and rising regulatory approvals in the region. Whereas Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as rising disease prevalence, an increase in the number of collaborations for drug development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.

Major market player included in this report are:

  • Abbott Laboratories
  • Agilent Technologies Inc.
  • F.Hoffmann-La Roche Ltd
  • Biomerieux SA
  • Qiagen NV
  • Siemens Healthcare Gmbh
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation (Beckman Coulter Inc.)
  • Almac Group
  • Illumina Inc.

Recent Developments in the Market:

  • In January 2022, Amoy Diagnostics Co. Ltd., and PREMIA Holdings (HK) Limited introduced the AmoyDx Pan Lung Cancer PCR Panel (the "PLC Panel") in Japan as a reimbursed companion diagnostic for various anti-cancer drugs.
  • In January 2021,In partnership with OmniSeq Corporation, Laboratory Corporation of America Holdings unveiled OmniSeq INSIGHTsm, a complete tissue-based test for genomic and immunological profiling that makes use of next-generation sequencing (NGS) technology. By advancing precision oncology, the test hopes to enhance patient outcomes..

Global Companion Diagnostics Market Report Scope:

  • Historical Data 2019-2020-2021
  • Base Year for Estimation 2021
  • Forecast period 2022-2029
  • Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered Technology, Indication, End User Region
  • Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
  • Customization Scope Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Technology offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Technology:

  • Immunohistochemistry (IHC)
  • Polymerase Chain Reaction (PCR)
  • In-situ Hybridization (ISH)
  • Real-time PCR (RT-PCR)
  • Gene Sequencing
  • Other Technologies

By Indication:

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Leukemia
  • Melanoma
  • Other Indications

By End User:

  • Pharmaceutical & Biopharmaceutical Companies
  • Reference Laboratories
  • CROs
  • Others

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • RoLA
  • Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Companion Diagnostics Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Companion Diagnostics Market, by Technology, 2019-2029 (USD Billion)
    • 1.2.3. Companion Diagnostics Market, by Indication, 2019-2029 (USD Billion)
    • 1.2.4. Companion Diagnostics Market, by End User, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Companion Diagnostics Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Companion Diagnostics Market Dynamics

  • 3.1. Companion Diagnostics Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing incidence of Cancer
      • 3.1.1.2. Rising Regulatory Approvals of New Tests for Different Indications
    • 3.1.2. Market Challenges
      • 3.1.2.1. High Cost of Drug Development and Associated Clinical Trials
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Co-development of Drug and Diagnostic Technology
      • 3.1.3.2. Favourable government support

Chapter 4. Global Companion Diagnostics Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. Industry Experts Prospective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Companion Diagnostics Market, by Technology

  • 6.1. Market Snapshot
  • 6.2. Global Companion Diagnostics Market by Technology, Performance - Potential Analysis
  • 6.3. Global Companion Diagnostics Market Estimates & Forecasts by Technology 2019-2029 (USD Billion)
  • 6.4. Companion Diagnostics Market, Sub Segment Analysis
    • 6.4.1. Immunohistochemistry (IHC)
    • 6.4.2. Polymerase Chain Reaction (PCR)
    • 6.4.3. In-situ Hybridization (ISH)
    • 6.4.4. Real-time PCR (RT-PCR)
    • 6.4.5. Gene Sequencing
    • 6.4.6. Other Technologies

Chapter 7. Global Companion Diagnostics Market, by Indication

  • 7.1. Market Snapshot
  • 7.2. Global Companion Diagnostics Market by Indication, Performance - Potential Analysis
  • 7.3. Global Companion Diagnostics Market Estimates & Forecasts by Indication 2019-2029 (USD Billion)
  • 7.4. Companion Diagnostics Market, Sub Segment Analysis
    • 7.4.1. Lung Cancer
    • 7.4.2. Breast Cancer
    • 7.4.3. Colorectal Cancer
    • 7.4.4. Leukemia
    • 7.4.5. Melanoma
    • 7.4.6. Other Indications

Chapter 8. Global Companion Diagnostics Market, by End User

  • 8.1. Market Snapshot
  • 8.2. Global Companion Diagnostics Market by End User, Performance - Potential Analysis
  • 8.3. Global Companion Diagnostics Market Estimates & Forecasts by End User 2019-2029 (USD Billion)
  • 8.4. Companion Diagnostics Market, Sub Segment Analysis
    • 8.4.1. Pharmaceutical & Biopharmaceutical Companies
    • 8.4.2. Reference Laboratories
    • 8.4.3. CROs
    • 8.4.4. Others

Chapter 9. Global Companion Diagnostics Market, Regional Analysis

  • 9.1. Companion Diagnostics Market, Regional Market Snapshot
  • 9.2. North America Companion Diagnostics Market
    • 9.2.1. U.S. Companion Diagnostics Market
      • 9.2.1.1. Technology breakdown estimates & forecasts, 2019-2029
      • 9.2.1.2. Indication breakdown estimates & forecasts, 2019-2029
      • 9.2.1.3. End User breakdown estimates & forecasts, 2019-2029
    • 9.2.2. Canada Companion Diagnostics Market
  • 9.3. Europe Companion Diagnostics Market Snapshot
    • 9.3.1. U.K. Companion Diagnostics Market
    • 9.3.2. Germany Companion Diagnostics Market
    • 9.3.3. France Companion Diagnostics Market
    • 9.3.4. Spain Companion Diagnostics Market
    • 9.3.5. Italy Companion Diagnostics Market
    • 9.3.6. Rest of Europe Companion Diagnostics Market
  • 9.4. Asia-Pacific Companion Diagnostics Market Snapshot
    • 9.4.1. China Companion Diagnostics Market
    • 9.4.2. India Companion Diagnostics Market
    • 9.4.3. Japan Companion Diagnostics Market
    • 9.4.4. Australia Companion Diagnostics Market
    • 9.4.5. South Korea Companion Diagnostics Market
    • 9.4.6. Rest of Asia Pacific Companion Diagnostics Market
  • 9.5. Latin America Companion Diagnostics Market Snapshot
    • 9.5.1. Brazil Companion Diagnostics Market
    • 9.5.2. Mexico Companion Diagnostics Market
    • 9.5.3. Rest of Latin America Companion Diagnostics Market
  • 9.6. Rest of The World Companion Diagnostics Market

Chapter 10. Competitive Intelligence

  • 10.1. Top Market Strategies
  • 10.2. Company Profiles
    • 10.2.1. Abbott Laboratories
      • 10.2.1.1. Key Information
      • 10.2.1.2. Overview
      • 10.2.1.3. Financial (Subject to Data Availability)
      • 10.2.1.4. Product Summary
      • 10.2.1.5. Recent Developments
    • 10.2.2. Agilent Technologies Inc.
    • 10.2.3. F.Hoffmann-La Roche Ltd
    • 10.2.4. Biomerieux SA
    • 10.2.5. Qiagen NV
    • 10.2.6. Siemens Healthcare Gmbh
    • 10.2.7. Thermo Fisher Scientific Inc.
    • 10.2.8. Danaher Corporation (Beckman Coulter Inc.)
    • 10.2.9. Almac Group
    • 10.2.10. Illumina Inc.

Chapter 11. Research Process

  • 11.1. Research Process
    • 11.1.1. Data Mining
    • 11.1.2. Analysis
    • 11.1.3. Market Estimation
    • 11.1.4. Validation
    • 11.1.5. Publishing
  • 11.2. Research Attributes
  • 11.3. Research Assumption

LIST OF TABLES

  • TABLE 1. Global Companion Diagnostics Market, report scope
  • TABLE 2. Global Companion Diagnostics Market estimates & forecasts by Region 2019-2029 (USD Billion)
  • TABLE 3. Global Companion Diagnostics Market estimates & forecasts by Technology 2019-2029 (USD Billion)
  • TABLE 4. Global Companion Diagnostics Market estimates & forecasts by Indication 2019-2029 (USD Billion)
  • TABLE 5. Global Companion Diagnostics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 6. Global Companion Diagnostics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 7. Global Companion Diagnostics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 8. Global Companion Diagnostics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 9. Global Companion Diagnostics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 10. Global Companion Diagnostics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 11. Global Companion Diagnostics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 12. Global Companion Diagnostics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 13. Global Companion Diagnostics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 14. Global Companion Diagnostics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 15. U.S. Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 16. U.S. Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 17. U.S. Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 18. Canada Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 19. Canada Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 20. Canada Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 21. UK Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 22. UK Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 23. UK Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 24. Germany Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 25. Germany Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 26. Germany Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 27. France Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 28. France Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 29. France Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 30. Italy Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 31. Italy Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 32. Italy Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 33. Spain Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 34. Spain Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 35. Spain Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 36. RoE Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 37. RoE Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 38. RoE Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 39. China Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 40. China Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 41. China Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 42. India Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 43. India Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 44. India Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 45. Japan Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 46. Japan Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 47. Japan Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 48. South Korea Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 49. South Korea Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 50. South Korea Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 51. Australia Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 52. Australia Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 53. Australia Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 54. RoAPAC Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 55. RoAPAC Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 56. RoAPAC Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 57. Brazil Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 58. Brazil Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 59. Brazil Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 60. Mexico Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 61. Mexico Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 62. Mexico Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 63. RoLA Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 64. RoLA Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 65. RoLA Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 66. Row Companion Diagnostics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 67. Row Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 68. Row Companion Diagnostics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 69. List of secondary sources, used in the study of global Companion Diagnostics Market
  • TABLE 70. List of primary sources, used in the study of global Companion Diagnostics Market
  • TABLE 71. Years considered for the study
  • TABLE 72. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Companion Diagnostics Market, research methodology
  • FIG 2. Global Companion Diagnostics Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Companion Diagnostics Market, key trends 2021
  • FIG 5. Global Companion Diagnostics Market, growth prospects 2022-2029
  • FIG 6. Global Companion Diagnostics Market, porters 5 force model
  • FIG 7. Global Companion Diagnostics Market, pest analysis
  • FIG 8. Global Companion Diagnostics Market, value chain analysis
  • FIG 9. Global Companion Diagnostics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 10. Global Companion Diagnostics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 11. Global Companion Diagnostics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 12. Global Companion Diagnostics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 13. Global Companion Diagnostics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 14. Global Companion Diagnostics Market, regional snapshot 2019 & 2029
  • FIG 15. North America Companion Diagnostics Market 2019 & 2029 (USD Billion)
  • FIG 16. Europe Companion Diagnostics Market 2019 & 2029 (USD Billion)
  • FIG 17. Asia pacific Companion Diagnostics Market 2019 & 2029 (USD Billion)
  • FIG 18. Latin America Companion Diagnostics Market 2019 & 2029 (USD Billion)
  • FIG 19. Global Companion Diagnostics Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable